Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Lexaria Bioscience (LEXX) over the last 15 years, with Q4 2025 value amounting to $4.4 million.

  • Lexaria Bioscience's Cash & Current Investments fell 4549.85% to $4.4 million in Q4 2025 from the same period last year, while for Nov 2025 it was $4.4 million, marking a year-over-year decrease of 4549.85%. This contributed to the annual value of $1.9 million for FY2025, which is 7032.52% down from last year.
  • Lexaria Bioscience's Cash & Current Investments amounted to $4.4 million in Q4 2025, which was down 4549.85% from $1.9 million recorded in Q3 2025.
  • Lexaria Bioscience's 5-year Cash & Current Investments high stood at $11.8 million for Q3 2021, and its period low was $1.5 million during Q3 2023.
  • For the 5-year period, Lexaria Bioscience's Cash & Current Investments averaged around $6.2 million, with its median value being $6.4 million (2022).
  • In the last 5 years, Lexaria Bioscience's Cash & Current Investments soared by 190210.59% in 2021 and then tumbled by 7601.28% in 2023.
  • Lexaria Bioscience's Cash & Current Investments (Quarter) stood at $11.4 million in 2021, then crashed by 57.85% to $4.8 million in 2022, then crashed by 57.8% to $2.0 million in 2023, then soared by 300.58% to $8.1 million in 2024, then tumbled by 45.5% to $4.4 million in 2025.
  • Its Cash & Current Investments was $4.4 million in Q4 2025, compared to $1.9 million in Q3 2025 and $4.6 million in Q2 2025.